Abstract
Aldo-keto reductase (AKR) family 1, member 7 (AKR1B7), a member of the AKR superfamily, has been suggested to play an important role in the detoxification of lipid peroxidation by-products. The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are xenosensors postulated to alleviate xeno- and endobiotic chemical insults. In this study, we show that the mouse Akr1b7 is a shared transcriptional target of PXR and CAR in the liver and intestine. Treatment of wild-type mice with the PXR agonist pregnenolone-16α-carbonitrile (PCN) activated Akr1b7 gene expression, whereas the effect was abrogated in PXR(-/-) mice. Similarly, the activation of Akr1b7 gene expression by the CAR agonist 1,4-bis[2-(3,5-dichlorpyridyloxyl)]-benzene, seen in wild-type mice, was abolished in CAR(-/-) mice. The promoter of Akr1b7 gene was activated by PXR and CAR, and this activation was achieved through the binding of PXR-retinoid X receptor (RXR) or CAR-RXR heterodimers to direct repeat-4 type nuclear receptor-binding sites found in the Akr1b7 gene promoter. At the functional level, treatment with PCN in wild-type mice, but not PXR(-/-) mice, led to a decreased intestinal accumulation of malondialdehyde, a biomarker of lipid peroxidation. The regulation of Akr1b7 by PXR was independent of the liver X receptor (LXR), another nuclear receptor known to regulate this AKR isoform. Because a major function of Akr1b7 is to detoxify lipid peroxidation, the PXR-, CAR-, and LXR-controlled regulatory network of Akr1b7 may have contributed to alleviate toxicity associated with lipid peroxidation.
Footnotes
- Received May 1, 2009.
- Accepted June 19, 2009.
This work was supported in part by the National Institutes of Health National Cancer Institute [Grant CA107011] and the National Institutes of Health National Institute of Environmental Health Sciences [Grant ES014626].
ABBREVIATIONS: AKR, aldo-keto reductase; PUFA, polyunsaturated fatty acid; MDA, malondialdehyde; PXR, pregnane X receptor; CAR, constitutive androstane receptor; RXR, retinoid X receptor; DR, direct repeat; LXR, liver X receptor; DKO, double knockout; PCN, pregnenolone-16α-carbonitrile; GW3965, 3-[3-[N-(2-chloro-3-trifluoromethylbenzyl)-(2,2-diphenylethyl)amino]propyloxy]phenylacetic acid hydrochloride; FABP, fatty acid-binding protein; VP, viral protein 16; TCPOBOP, 1,4-bis[2-(3,5-dichlorpyridyloxyl)]-benzene; PCR, polymerase chain reaction; ChIP, chromatin immunoprecipitation; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; bp, base pair(s); PEI, polyethylenimine; DMEM, Dulbecco's modified Eagle's medium; EMSA, electrophoretic mobility shift assay; DMSO, dimethyl sulfoxide; kb, kilobase(s); LG268, 6-[-1(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-cyclopropyl]-pyridine-3-carboxylic acid; T0901317, N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]phenyl]-benzenesulfonamide.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|